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INDETERMINATE CELL HISTIOCYTOSIS: A CASE REPORT
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Indeterminate cell histiocytosis is a rare neoplasm composed of cells with mixed characteristics of
Langerhans cells and non-Langerhans cells. An otherwise healthy, 36-year-old woman presented with
asymptomatic generalized papules and nodules that had appeared on all four extremities, the trunk, and
cheeks in the previous 6 months. The lesions were firm, painless, non-pruritic, and slightly flesh-yellow
or reddish-brown in color. Histopathologic, immunohistochemical examination and electron microscopic
studies showed characteristic findings of indeterminate cell histiocytosis: diffuse proliferative histiocytes
infiltrating the dermis without epidermotropism or atypia; neoplastic cells expressing markers
characteristic of both Langerhans cells (CD1a, S-100) and focal monocytes/macrophages (Factor XIIIa,
CD68); and no Birbeck granules within the cytoplasm of the neoplastic cells. Flow cytometry revealed
more CD34+ cells in the peripheral blood of the patient than in peripheral blood from a control. Interestingly,
the patient responded favorably to psoralen ultraviolet A-range treatment. Herein, we present this case
and review the literature.
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The histiocytic disorders cover a wide range of benign and
malignant diseases and can be differentiated on the basis of
clinicopathologic features, ultrastructural picture, and
prognosis. According to the origin of the proliferating cells,
these conditions have been classified as Langerhans, non-
Langerhans, and indeterminate cell histiocytoses [1]. In-
determinate cell histiocytosis (ICH) was first described by
Wood et al in 1985 as a neoplastic disease originating from
dermal indeterminate cells that are characteristically positive
for S-100 and CD1a but lack Birbeck granules on electron
microscopy [2]. A few cases have subsequently been
reported. Cases with a solitary lesion have also been
described [3,4]. We now present the first case in Taiwan and
propose a new treatment for this disorder.
CASE PRESENTATION
An otherwise healthy, 36-year-old woman presented with
a 6-month history of generalized, firm, asymptomatic, flesh-
yellow to reddish-brown, partially coalesced papules and
nodules over the four extremities, anterior chest, shoulder,
lower abdomen, back, and cheeks (> 60 in number) (Figure
1). No ulceration or mucosal involvement was noted, and no
lymphadenopathy was found on physical examination.
There was no family history and no history of trauma or
infection before the occurrence of the skin lesions.
The following laboratory data were within normal limits:
complete blood count with differential classification;
urinalysis; stool analysis; serum electrolytes; general
biochemistry (including lipids); Venereal Disease Research
Laboratory/Treponema pallidum  hemagglutination;
qualitative test for antinuclear antigen; rheumatoid factor;
tumor markers including _-fetoprotein, squamous cell
carcinoma (SCC), tumor polypeptide antigen (TPA), and
carcinoembryonic antigen; and the numbers of all T cells,
active T cells, all B cells, CD4/CD8 cells, and DR+ cells. The
dinitrochlorobenzene test and challenge test (performed 1
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week later) revealed erythema after 24 hours. Abdominal
sonography, chest roentgenography, bone scan, and
gallium-67 scan were not remarkable. The pathergy test and
purified protein derivative test yielded negative results.
Multiple excisional biopsies were taken from the
forearms and thighs. The specimens were fixed in formalin
and embedded in paraffin for routine hematoxylin and
eosin stain and immunohistochemical studies including
S-100 protein, lysozyme, CD1a, human leukocyte antigen
(HLA) DR, CD4, CD68, CD34, and Factor XIIIa. The histo-
logic examination of all specimens revealed diffuse his-
tiocytes infiltrating the entire dermis without subcutaneous
fat involvement, as well as mild perivascular lymphocytic
infiltration. The histiocytes were spindle or epitheloid
in shape with round or oval nuclei and a pale cytoplasm.
No kidney-shaped nuclei, intercellular edema, or
epidermotropism were seen (Figures 2A and B). Staining
with periodic acid-Schiff (PAS) and PAS diastase, specific
for labeling neoplastic cells, was negative. Immuno-
phenotypic studies revealed that the neoplastic cells were
positive for S-100 and CD1a (Figures 2C and D) and focally
weakly positive for CD4, CD68, Factor XIIIa, and CD34.
Slides for ultrastructural studies were processed using
2% paraformaldehyde and 2.5% glutaraldehyde, uranyl
acetate/lead citrate staining, and epoxy resin (Epikote;
Merck, Darmstadt, Germany) embedding. They were then
examined using a goniometer-equipped transmission
electron microscope (Jeol Jem-2000 EX II; JEOL Ltd, Tokyo,
Japan). The cells had irregularly shaped nuclei, scanty
chromatin, and abundant cytoplasm containing mito-
chondria, rough endoplasmic reticulum, ribosomes, and
variable amounts of irregularly-sized dense bodies (Figure
3). Although an extensive search was carried out, Birbeck
granules were not found in any specimen. Based on these
clinicopathologic, immunohistochemical, and ultrastruc-
tural data, the diagnosis of ICH was made.
Mononuclear cells, which consisted mainly of lympho-
cytes and monocytes, were isolated from peripheral whole
blood from the patient and from a normal control using Ficoll-
HypaqueTM (Amersham Pharmacia Biotech AB, Uppsala,
Sweden) centrifugation. Cells were analyzed by flow cytometry
(Figures 4A–E). Interestingly, there were more CD34+ cells in
the peripheral blood of the patient than in that of the control.
The patient then received oral 8-methoxypsoralen
(8-MOP) plus ultraviolet A (UVA). Psoralen UVA (PUVA)
treatment was administered three times a week for 4 months.
UVA was given at an initial dosage of 2.0 J/cm2 and, at every
second or third exposure, 0.5 J/cm2 was added to the
previous dose (final dose, 5 J/cm2). After 2 months of
treatment, the skin lesions gradually regressed and PUVA
therapy was continued over the next 2 months. No new skin
lesions or side effects developed during or after treatment.
The skin lesions regressed gradually, and left only some
post-inflammatory hyperpigmentation (Figures 5A and B).
After 4 months of PUVA, the patient discontinued treatment
and received regular outpatient follow-up.
DISCUSSION
ICH seems to show no gender- or age-specific predilection
[5]. The clinical features of this disease include multiple,
asymptomatic, cutaneous papules and nodules in otherwise
healthy individuals [1]. Cases with a solitary lesion have
also been described [3,4]. In most cases, lesions are located
on the trunk and extremities or distributed as generalized
eruptions. As in our patient, early lesions usually consist of
flesh-yellow, firm subcutaneous nodules and papules that
tend to become reddish-brown in the later stages.
Figure 1. Generalized asymptomatic flesh-yellow to reddish-brown
papules and nodules on the four extremities, trunk, and face.
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Figure 2. (A) Diffuse histiocytes infiltrate throughout the dermis without subcutaneous fat involvement and mild perivascular lymphocytic
infiltration (hematoxylin and eosin, = 40). (B) Histiocytes show large, round, or oval nuclei and pale cytoplasm (hematoxylin and eosin, = 400).
(C) Neoplastic cells are positive for S-100 (= 400), and (D) for CD1a (= 200).
Figure 3. Irregularly shaped nuclei, scanty chromatin, and abundant
cytoplasm containing variable amounts of irregular-sized dense bodies
(arrows) but no Birbeck granules (= 10,000). m = mitochondria.
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Because histiocytosis disorders cover a wide range of
forms, some authors employ a modification of the scheme
shown in the Table to diagnose histiocytosis. This scheme
primarily uses the presence or absence of S-100, CD1a, and
Birbeck granules to subdivide histiocytosis disorders, and a
variety of other markers to provide an overview [6]. Our
case was not likely to be histiocytosis X since we could not
find its characteristic features, such as extracutaneous
involvement, epidermotropism, or Birbeck granules [2].
Congenital self-healing reticulohistiocytosis, in which only
a minority of the histiocytic cells are S-100 positive and
Birbeck granules are found, is also distinctive for its
appearance at birth or during the first few days of life, and
for its rapid resolution [7].
Cutaneous non-X histiocytosis comprises a spectrum of
disorders exhibiting proliferative histiocytic or macropha-
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gic cells, such as generalized eruptive histiocytosis, benign
cephalic histiocytosis, xanthoma, etc. These disorders are
characterized by the absence of epidermotropism, negativity
for both S-100 and CD1 antigens, and lack of Birbeck granules
but positivity for monocyte/macrophage and dendrocytic
markers such as CD68 and Factor XIIIa (Table) [6]. Clinically,
Figure 4. Marker expression (% positive cells) in mononucleocytes from both a control and a patient detected by flow immunofluorescence.
(A) Background. (B) & (C) There are more CD34+ cells in the patient compared with the control. (D) & (E) There are more CD1a+ cells in the patient
compared with the control. FITC = fluorescein isothiocyanate.
Figure 5. The clinical picture (A) pre-psoralen ultraviolet A (PUVA), and (B) post-PUVA.
our case had a similar presentation to generalized eruptive
histiocytosis. Therefore, positivity for S-100 and CD1a was
considered to be the main feature and helped to distinguish
ICH from cutaneous non-X histiocytosis.
Regarding the origin of indeterminate cells in the dermis,
Murphy et al have reported that indeterminate cells may
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Table. Antigenic markers in histiocytic disorders [6]
Disease S-100 CD1a Birbeck MS-1 KP1 (CD68) MAC387 CD34 Factor XIIIa
LCH + + + – – – – –
CSHRH + + + – – – – –
ICH + + – – – – – –
SHML + – – – – – – +/–
XD – – – + + – – +
PX – – – +/– +/– + – –
MR – – – + + – – –
GCRH – – – + + – – +/–
EH – – – + + – +/– –
BCH – – – ? ? ? ? ?
Our case + + – ND +/– ND +/– +/–
LCH = Langerhans cell histiocytosis; CSHRH = congenital self-healing reticulohistiocytosis; ICH = indeterminate cell histiocytosis; SHML =
sinus histiocytosis with massive lymphadenopathy; XD = xanthoma disseminatum; PX = papular xanthoma; MR = multicentric
reticulohistiocytosis; GCRH = giant cell reticulohistiocytoma; EH = eruptive histiocytosis; BCH = benign cephalic histiocytosis; + = positive;
– = negative; +/– = variable or conflicting data; ? = little or no data; ND = not done.
represent precursors of Langerhans cells that acquire Birbeck
granules when they transfer from dermal to epidermal
sites, as a result of the interaction between their cellular
receptors and epidermis-specific ligands [8]. On the other
hand, some consider that indeterminate cells may represent
Langerhans cells that have left the epidermis and lost their
Birbeck granules on their way to the lymph node [5].
The CD34 cell marker is selectively expressed on human
lymphoid and myeloid hematopoietic progenitor cells. In
an in vitro study, Caux et al used granulocyte macrophage
colony-stimulating factor (GM-CSF) and tumor necrosis
factor-_ (TNF-_) to generate Langerhans cells from CD34+
human hematopoietic progenitors [9]. Another author
claimed that Langerhans cells belong to the family of
“myeloid” cells. They share common precursors with
macrophages in bone marrow and probably blood, but the
precise point at which Langerhans cells differentiate from
the myelomonocytic lineage remains unclear [10]. Accor-
ding to one study, the level of CD34+ cells in the peripheral
blood of patients with Langerhans cell histiocytosis was
three times higher than that in normal controls. In addition,
after 6 days of culture in GM-CSF and TNF-_, cells derived
from CD34+ cells from peripheral blood were similar to
“indeterminate cells” [11]. Our flow cytometry data from
peripheral blood revealed that the percentages of CD34+
and CD1a+ cells in our patient were greater than those in
the normal control. We therefore speculated that the
indeterminate cells might be similar to Langerhans cells,
which originate from CD34+ human hematopoietic
progenitors. However, this hypothesis needs further
investigation.
Because ICH is a rare disorder and has a variable clinical
course, treatment has not been established. Total excision
[3,4], intravenous vinblastine [2], electrodessication [12],
topical pure coal tar, and 5% 5-fluorouracil cream [13] have
all been proposed. In some patients, the process is clinically
benign and may resolve spontaneously. Conservative
management might be favorable for these patients [1,5,14,
15]. However, the disease can also be extensive and debi-
litating. For example, one adult female reportedly died of
acute mast cell leukemia [16], and an infant had a malignant
course leading to death despite aggressive chemotherapy
and bone marrow transplantation [17].
In previous studies, PUVA has reduced the number
of Langerhans cells as well as their function [18]. The
beneficial effects of PUVA therapy on Langerhans cell
histiocytosis have been previously described [19,20].
Interestingly, in our case (ICH), the cutaneous lesions
responded well to PUVA therapy and almost complete
remission was achieved. We concluded that PUVA therapy
may be considered an effective treatment for ICH that is
localized to the skin.
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